BioAtla Investor Presentation Deck

BioAtla® is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABS) Proprietary technology Broad applicability in solid tumors Increases therapeutic bicatla window Two Phase 2 CAB-ADCs, one Phase 1 CAB-I/O and one Phase 1 CAB-bispecific T-cell engager BA3011 advancing potentially registrational studies in sarcoma and NSCLC Diversified pipeline Clinical readouts for multiple indications through 2023 Strategic optionality Strong cash position $168.7 million in cash and cash equivalents as of 06/30/23 Sufficient through key clinical milestones into 2025 BioAtla| Overview 41

View entire presentation